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Improved inflammatory bowel disease,
wound healing and normal oxidative burst
under treatment with empagliflozin in
glycogen storage disease type Ib
Sarah C. Grünert1* , Roland Elling1, Bärbel Maag1, Saskia B. Wortmann2,3, Terry G. J. Derks4, Luciana Hannibal5,
Anke Schumann1, Stefanie Rosenbaum-Fabian1 and Ute Spiekerkoetter1
Abstract
Background: Glycogen storage disease type Ib (GSD Ib) is a rare inborn error of glycogen metabolism due to
mutations in SLC37A4. Besides a severe form of fasting intolerance, the disorder is usually associated with
neutropenia and neutrophil dysfunction causing serious infections, inflammatory bowel disease, oral, urogenital and
perianal lesions as well as impaired wound healing. Recently, SGLT2 inhibitors such as empagliflozin that reduce the
plasma levels of 1,5-anhydroglucitol have been described as a new treatment option for the neutropenia and
neutrophil dysfunction in patients with GSD Ib.
Results: We report on a 35-year-old female patient with GSD Ib who had been treated with G-CSF for neutropenia
since the age of 9. She had a large chronic abdominal wound as a consequence of recurrent operations due to
complications of her inflammatory bowel disease. Treatment with 20 mg empagliflozin per day resulted in
normalisation of the neutrophil count and neutrophil function even after termination of G-CSF. The chronic
abdominal wound that had been unchanged for 2 years before the start of empagliflozin nearly closed within 12
weeks. No side effects of empagliflozin were observed.
Conclusion: SGLT2 inhibitors are a new and probably safe treatment option for GSD Ib-associated neutropenia
and neutrophil dysfunction. We hypothesize that restoration of neutrophil function and normalisation of
neutrophil apoptosis leads to improvement of wound healing and ameliorates symptoms of inflammatory
bowel disease.
Keywords: Glycogen storage disease type Ib, Neutropenia, Neutrophil dysfunction, Empagliflozin, Wound
healing, Inflammatory bowel disease, Oxidative burst, Glucose-6-phosphate transporter
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Background
Glycogen storage disease type Ib (GSD Ib) is a rare dis-
order of glycogen metabolism due to mutations in
SLC37A4 encoding the glucose-6-phosphate transporter
of the endoplasmic reticulum. This glucose-6-phosphate
transporter is ubiquitously expressed and transports
glucose-6-phosphate from the cytosol to the lumen of the
endoplasmic reticulum where it can be hydrolyzed by
glucose-6-phosphatase [1]. The estimated prevalence of
GSD Ib is about 1: 500,000 [2]. GSD Ib is clinically charac-
terized by severe fasting hypoglycemia, hepatomegaly, fail-
ure to thrive, growth retardation, truncal obesity, doll-like
facies, short stature, bleeding tendency and hypotrophic
muscles [3]. Laboratory findings include hyperuricemia,
hyperlipidemia, and elevated lactate levels [3]. Addition-
ally, most patients with GSD Ib develop neutropenia and
inflammatory bowel disease. Neutropenia is the hallmark
feature of GSD Ib, however, the age at onset as well as the
clinical course are variable [3]. It may be present already
at birth or not appear until late in childhood as cyclic or
permanent neutropenia [3, 4].
Polymorphonuclear neutrophils (PMNs) from patients
with GSD Ib are not only reduced in number, but also
dysfunctional [4]. Neutropenia is caused by both a de-
crease in the production of mature neutrophils as well as
enhanced neutrophil apoptosis [5–7]. PMN dysfunction is
reflected by impaired respiratory burst, chemotaxis, and
calcium mobilization activities [8, 9]. G6PT-deficient
PMN show reduced glucose utilization characterized by
decreased glucose uptake and reduced levels of intracellu-
lar G6P, lactate, adenosine triphosphate, and reduced
NAD phosphate [5]. This energy impairment is likely re-
sponsible for their decreased capacity to produce super-
oxide, decreased protein glycosylation, and increased
endoplasmic reticulum stress [10]. Deficiency of G6PT
also causes impairment in neutrophil adhesion and migra-
tion via aberrant expression of β2 integrins [11].
Veiga-da-Cunha et al. have recently shown that the
impaired glucose utilisation of G6PT-deficient neutro-
phils is caused by failure to eliminate 1,5-anhydrogluci-
tol-6-phosphate (1,5-AG6P), a close structural analogue
of glucose-6-phosphate [10] (Fig. 1). Accumulation of 1,
5-AG6P within the granulocytes strongly inhibits the ac-
tivities of hexokinases that catalyse the first step of gly-
colysis, resulting in energy deficiency of the cells and
apoptosis (Fig. 1). Studies in a G6PC3-deficient mouse
Fig. 1 Mechanism of neutropenia in glycogen storage disease type 1b. 1,5-anhydroglutitol, a non-degradable glucose analogue, is phosphorylated to
1,5-anhydroglucitol-phosphate. This metabolite is usually detoxified by transport to the endoplasmic reticulum by the glucose-6-phosphate transporter
(G6PT) and subsequent dephosphorylation by the enzyme G6PC3. In patients with GSD Ib who are deficient in G6PT, 1,5-anhydroglucitol-phosphate
accumulates in toxic concentrations. This metabolite is a strong inhibitor of hexokinases resulting in depletion of the intracellular glucose-6-phophate
pool that is vital for normal survival and function of the neutrophils
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model that phenotypically and biochemically mimics the
PMN impairment of patients with GSD Ib have shown
that treatment with an inhibitor of the kidney sodium
glucose co-transporter 2 (SGLT2) was able to lower the
blood level of 1,5AG6P and consequently restore a nor-
mal neutrophil count [10]. This has already prompted
first treatment trials in single GSD Ib patients with posi-
tive effects, such as improvement of inflammatory bowel
disease, ulcerative stomatitis and anemia [12]. SGLT2 in-
hibitors such as empagliflozin are anti-diabetic drugs
that inhibit renal glucose reabsorption resulting in an in-
creased urinary excretion of glucose [13]. Glucosuria de-
creases renal 1,5-AG reabsorption and thereby lowers its
serum concentrations [12, 14]. Treating patients with a
disorder associated with fasting hypoglycemia with a
glucose-lowering drug might be counterintuitive, how-
ever, no severe side effects have been reported in the
first few treated patients so far [12]. We report on a 35-
year-old female patient with neutropenia, inflammatory
bowel disease, massive splenomegaly and thrombocytopenia
after 26 years of granulocyte-colony stimulating factor (G-
CSF) treatment and a severe wound healing defect after ab-
dominal surgery who showed remarkable improvement of
wound healing and neutrophil count and function upon
treatment with empagliflozin.
Methods
PMN isolation and apoptosis assays
Neutrophil granulocytes were isolated from peripheral
blood using density-gradient centrifugation. Equal num-
ber of controls or patient cells were cultured in RPMI
supplemented with 10% FCS plus 0.5% Ciprofloxacin
and in some experiments exposed to GM-CSF (100 ng/
ml; PeproTech) or Q-VD (1 μM; MP Biomedicals). After
0, 6 and 12 h apoptosis was analyzed by Annexin V/ Pro-
pidium iodide staining (BD Pharmingen / BioLegend) on
a Gallios flow cytometer. Purity of neutrophils was mea-
sured by staining for CD66b (BD Pharmingen) and typ-
ically yielded > 99% positive cells.
Oxidative burst
Reactive oxygen species of PMN were measured using the
DHR assay as described by Vowells et al. [15]. Briefly,
leucocytes were loaded with dihydrorhodamine 123
(DHR-123, Sigma) after red blood cell lysis at 37 °C for 5
min and stimulated with phorbol myristate acetate (PMA)
for 15min. The samples were immediately analyzed by
flow cytometry using the FL-2 channel (585 nm).
Results
Case report
The patient is a 35 year-old woman who was diagnosed
with GSD Ib at the age of 10 months. Dietary treatment
was started with good metabolic control. Since the age
of 9 years the patient has received G-CSF treatment for
neutropenia and recurrent infections. Since the age of 10
she has suffered from inflammatory bowel disease. The
clinical course was further complicated by recurrent ab-
dominal abscesses. At age 25, subtotal colectomy was
performed due to long-distance stenosis of the trans-
verse colon with an abscess in the right upper abdomen.
Postoperative wound healing was impaired and required
surgical wound revision and closure. Pancreatic fibrosis
was observed at age 28, exocrine pancreatic insufficiency
was diagnosed at age 31, and supplementation with pan-
creatin was initiated. Hepatosplenomegaly was observed,
and the thrombocyte count was significantly reduced to
around 40 G/l, possibly due to the massive splenomegaly.
At age 33, the patient presented with acute abdominal
pain in the lower abdomen. MRI was suggestive of a pel-
vic abscess, enlarged pelvic retroperitoneal and mesen-
terial lymph nodes as well as inflammatory alterations of
the intestine. The patient had bloody stools, and her
overall clinical condition was reduced. Antibiotic therapy
with meropenem, ampicillin and metronidazole was
started. Explorative laparotomy with extensive resection
of the small bowel (side-to-side jejuno-jejunostomy 70
cm distal of the ligament of Treitz and end-to-end
jejuno-jejunostomy 150 cm distal of the ligament of
Treitz, resection of the stenosing ileodescendostomy)
was performed. Abdominal bleeding occurred in the
postoperative course, which required 4 further laparoto-
mies within 3 weeks. Secondary surgical closure of the
wound could be performed 4 weeks after the initial oper-
ation. However, within the consecutive weeks a large
wound dehiscence developed with severely impaired
wound healing. At its maximum the wound had a diam-
eter of 29 × 18 cm. Surgical revision of the abdominal
wall defect after 1 year was not of permanent success. A
colonoscopy was performed alongside this procedure,
which revealed mild to moderate inflammatory activity.
Supplementation with protein powder as well as arginine
and glutamine was started to promote wound healing,
but was also without success.
At age 35 the patient first presented to our metabolic
clinic. Her body weight was 50 kg, body length 153 cm
and BMI 21.4 kg/m2. She was in good metabolic control
under a GSD diet with regular meals every 2 h during
the day and continuous nocturnal feeding with tube
feeding formula and maltodextrin (composition of diet
assessed by a 3-day dietary protocol: carbohydrates 47%
of energy intake, fat 34% of energy intake, and protein
18% of energy intake). Continuous glucose monitoring
was performed using a Dexcom G6 device. Transamin-
ase activities (AST 13 U/L, ALT 19 U/L, normal 10–35
U/L), serum triglycerides 140 mg/dL (< 150mg/dL), uric
acid 5.4 mg/dl (2,4–5,7 mg/dL) and lactate 1.0 mmol/L
(normal 0,5–1,6 mmol/L) were normal. Total protein,
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albumin and pre-albumin concentrations in serum were
also within the respective reference ranges (7.6 g/L (nor-
mal 6.4–8.3 g/L), 4.2 g/L (normal 3.5–5.2 g/L) and 0.21
g/L (normal 0.2–0.4 g/L), respectively). Abdominal ultra-
sound still showed massive hepatosplenomegaly (liver
17.8 cm, normal < 15 cm; spleen 27.1 cm, normal < 14
cm). Thrombocyte count was severely reduced with 42
G/L, whereas the hemoglobin level was normal at 11.6 g/
dL. The patient had about 10–11 loose to watery stools
per day. The Crohn’s Disease Activity Index (CDAI) was
398. This index is the gold standard to determine
current activity of Crohn’s disease. A CDAI score < 150
is defined as remission of Crohn’s disease, while a value
of greater than 450 is defined as severe disease. The
Crohn-like disease was treated with budesonide 3mg/
day, 5-aminosalicylic acid 3 × 1 g/day, vitamin E 800mg/
day and loperamide 2 mg. Stool calprotectin was within
the normal range (42 mg/kg, normal < 50mg/kg), CRP
was normal (0.7 mg/dl, normal < 1mg/dl), and the blood
sedimentation rate was 25 within the 1st hour (normal
< 20mm). The clinical condition was stable but the over-
all well-being was markedly impaired, the appetite was
reduced. The abdominal wall defect was 8 cm × 6.5 cm
and oozing (Fig. 2). Colonoscopy or capsule endoscopy
was not performed due to the high risk of abdominal
complications. Anogenital lesions had not occurred
within the last 20 years, oral lesions only after special
triggers such as dental cleaning.
After informed consent for this individual treatment the
patient was admitted for the initiation of empagliflozin
therapy. The starting dose was 5mg/day, and the dose
was subsequently increased to 2 × 5mg/day on day 2, and
10mg/5mg on day 3. Absolute neutrophil count at admis-
sion was 1600/μl under 1.05 μg G-CSF/kg/day. The dietary
regimen was continued as usual, and no relevant hypogly-
cemias were observed. The minimal blood sugar was 4.3
mmol/L. The patient could be discharged on day 4.
Within the following weeks the neutrophil count in-
creased, and the G-CSF dose could subsequently be de-
creased stepwise as shown in Fig. 3. The appetite and
well-being improved. The stool frequency also decreased
to 5 to 7 stools per day, and loperamide could be termi-
nated. Wound-healing distinctly improved and the ab-
dominal wall defect slowly granulated (Fig. 2). After 1
month, the empagliflozin dose was increased to 2 × 10
mg/day. Administration of GCSF was terminated 41 days
after the start of empagliflozin (Fig. 3). No major side ef-
fects of empagliflozin were observed, such as urogenital
infections, hypoglycemia and ketoacidosis. Albumin con-
centration remained stable within the normal range (4.2 g/
L, normal 3.5–5.2 g/L). The body weight remained stable
during the treatment period, and no relevant change in
thrombocyte count or haemoglobin level was observed.
The CDAI score decreased to 184 on day 50 of empagli-
flozin treatment. Fasting tolerance also slightly increased.
The wound size on day 85 of treatment was about 3 × 1.5
cm.
As PMN from GSD Ib patients are known to show im-
paired ROS production and an increased apoptosis pheno-
type, we analysed both apoptosis as well as reactive
oxygen production in neutrophils from our patient (Fig. 4)
on day 50 of empagliflozin treatment. As shown in Fig. 4a,
spontaneous apoptosis of isolated PMN did not differ
compared with healthy control cells. Furthermore, apop-
tosis could be efficiently reduced by supplementation of
cell culture media with GM-CSF (Fig. 4b). PMN apoptosis
could be fully abrogated by the pan-caspase inhibitor Q-
VD, an effect which was even more pronounced in patient
PMN compared to control cells (Fig. 4c). We next mea-
sured reactive oxygen species of patient and control PMN
after PMA stimulation and observed no significant differ-
ences, further confirming the stabilized phenotype of pa-
tient PMN under treatment with empagliflozin.
Discussion
For more than 25 years, the standard therapy for neutro-
penia associated with recurrent infections in GSD Ib pa-
tients has been the supplementation of G-CSF. G-CSF is
effective to raise blood neutrophil counts and to reduce
infections in most patients [16]. However, doses must be
Fig. 2 Development of the abdominal wound under empagliflozin treatment. a Before start of empagliflozin treatment b on day 50 on
empagliflozin and c on day 85 on empagliflozin
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limited due to side effects such as increases of spleen
size with abdominal pain and hypersplenism. Long-term
G-CSF treatment may also result in an increased risk of
myelodysplastic syndrome (MDS) or acute myeloid
leukemia (AML) possibly due to increased marrow stress
resulting in telomere shortening [2]. Several cases of
AML/MDS after treatment with G-CSF for 6–25 years
have been reported [2, 16–18].
After the elucidation of the mechanism of neutrophil
phenotype in GSD Ib SGLT2 inhibitors emerged as a new
treatment option for neutropenia and neutrophil dysfunc-
tion in GSD Ib [10, 12]. These anti-diabetic drugs that
have been approved for the treatment of diabetes type 2 in
adults have a favourable safety profile. Stimulation of renal
glucosuria along with reduced reabsorption of 1,5-AG
decreases plasma concentrations of this toxic metabolite,
thus minimizing neutrophil dysfunction in GSD Ib.
Wortmann et al. have reported the first four patients
treated with empagliflozin and observed dramatical im-
provement of the heterogeneous clinical findings related
to neutrophil dysfunction in all four patients [12]. This
included abdominal pain, symptoms of inflammatory
bowel disease, oral and anourogenital lesions and infec-
tions, dependence on tube feeding and anemia [12].
In consistence with these observations, treatment with
empagliflozin resulted in a striking clinical improvement
in our patient: 1) The abdominal wound that persisted
for more than 2 years despite treatment with G-CSF,
arginine, glutamine and protein supplementation almost
closed within few weeks, 2) The frequency of stools de-
creased and treatment with loperamide could be
stopped, the CDAI decreased to 184, and 3) the overall
well-being as well as the appetite increased.
The CDAI is a score to determine the current activity of
Crohn’s disease. The frequency of soft or liquid stools is
one important component used in the calculation of this
score. As our patient has a short bowel syndrome and is
lacking large parts of her colon, she will probably not be
able to produce solid stools even in the absence of inflam-
matory bowel disease. Therefore, the CDAI may overesti-
mate the inflammatory activity of her Crohn’s disease.
The observed clinical improvement under empagliflozin
was accompanied by a dramatic amelioration of laboratory
parameters: The neutrophil count initially increased
despite reduction and finally termination of G-CSF. Even
without G-CSF the neutrophil count stabilized well within
the reference range with an average number of neutro-
phils of about 2000–2500/μl. Neutropenia in GSD Ib is
thought to be caused by enhanced apoptosis [6].
Apoptosis studies performed in our patient showed no
evidence of increased apoptosis reflected by an equal
percentage of Annexin V positive PMNs after up to 12 h
culture compared with healthy donor cells. Likewise, we
did not observe any evidence for impaired ROS production
Fig. 3 Absolute neutrophil count, G-CSF dose and empagliflozin dose over the time of treatment. a Absolute neutrophil count. b) G-CSF and empagliflozin
dose. The G-CSF dose was reduced stepwise and G-CSF could be discontinued after 26 years of treatment on day 41 on empagliflozin
Grünert et al. Orphanet Journal of Rare Diseases          (2020) 15:218 Page 5 of 8
in patient PMNs as compared to control cells. Since neu-
trophils of GSD Ib patients are known to have impaired
oxidative burst and bactericidal activity [5], we interpret this
finding as the effect of empagliflozin therapy although we
did not measure ROS production or apoptosis before
initiation of this treatment.
Although the empagliflozin dose was progressively in-
creased to 20mg per day we observed none of the known
side effects such as hypoglycemia or urinary tract infections.
The daily dose of 20mg corresponds to 0.4mg/kg/day and
it is within the dosage window used in the patients treated
by Wortmann et al. between 0.3 and 0.7mg/kg/day [12]. A
clear dose-response as observed in one patient reported by
Wortmann et al. could not be seen in our patient when the
dose was increased from 15mg to 20mg/day.
Splenomegaly as seen in our patient is a common finding
in GSD Ib. A large cohort study on GSD Ib including both
pediatric and adult patients revealed that splenomegaly was
present in 47% prior to G-CSF and 76% on G-CSF treat-
ment [16]. Some patients showed a dramatic increase of
spleen size associated with abdominal pain under G-CSF
[16, 19, 20]. Several patients required splenectomy because
of the degree of splenic enlargement and pain [16]. In
contrast, thrombocytopenia, as observed in our patient for
years, is an uncommon finding. Although it is etiologically
not fully understood, it is well conceivable that it is at least
partially caused by sequestration of thrombocytes by the ex-
tremely enlarged spleen. The follow-up time, however, is
still too short to evaluate if splenomegaly will be reversible
after the termination of G-CSF treatment and if the
thrombocyte count will consecutively increase.
Empagliflozin is not approved for the treatment of
neutropenia in GSD Ib and its use for this indication is off
label. As treatment data are only available for very few
patients so far, there is still an important gap of knowledge
with respect to the risks and potential adverse effects in this
population. Due to their metabolic defect, GSD Ib patients
are especially prone to some of the common side effects
of empagliflozin, such as hypoglycemia and urogenital
infections. Additionally, chronic diarrhea associated with
inflammatory bowel disease may predispose patients to




Fig. 4 Apoptosis and ROS production of patient and control PMN. a Percentage of apoptotic PMN (Annexin V positive) after 0, 6 and 12 h culture
showing equal rates of apoptotic cells for healthy donors and patient. b percentage of apoptotic PMN (Annexin V positive) in healthy donors and
patient after 6 h culture in the presence of 100 ng/ml GM-CSF. c Fraction of apoptotic cells (Annexin V positive) collected from healthy donors and
patient after 12 h of caspase inhibition with 1 μM Q-VD. d ROS production in patient and healthy donor PMN measured by rhodamine fluorescence.
Fluorescence intensity of DHR123-loaded PMN in basal conditions (PBS) or after activation by PMA
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empagliflozin have been reported in GSD Ib so far, but
systematic data collection on the safety and efficacy is
necessary to further evaluate the risks and benefits of this
new treatment approach.
Conclusion
Although data on clinical and laboratory outcome
parameters are still very limited, empagliflozin is a
promising new option to treat neutropenia and neutro-
phil dysfunction in patients with GSD Ib. To facilitate
systematic data collection on the safety and efficacy of
this new treatment approach a patient registry has
already been initiated. Further studies are needed to
assess the long-term risks and benefits of this new
treatment. Data from preliminary interventions indicate
that empagliflozin seems to be superior to G-SCF with
respect to the correction of neutrophil dysfunction and
possible side effects.
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